Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 125 versus BACTOCILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 125 versus BACTOCILL.
AUGMENTIN '125' vs BACTOCILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
One AUGMENTIN '125' tablet (amoxicillin 125 mg, clavulanate 31.25 mg) orally every 8 hours for mild to moderate infections.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours (prolonged in renal impairment; up to 7-20 hours in anuria). Clavulanate: 0.9-1.2 hours (increased in renal impairment).
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; clavulanate: ~30-50% excreted unchanged in urine. Small amounts eliminated in bile and feces.
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic